Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation.
Biomarkers are required for pre-symptomatic diagnosis, treatment, and monitoring of neurodegenerative diseases such as Alzheimer's disease. Cerebrospinal fluid (CSF) is a favored source because its proteome reflects the composition of the brain. Ideal biomarkers have low technical and inter-ind...
Main Authors: | Richard J Perrin, Jacqueline E Payton, James P Malone, Petra Gilmore, Alan E Davis, Chengjie Xiong, Anne M Fagan, R Reid Townsend, David M Holtzman |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3659127?pdf=render |
Similar Items
-
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.
by: Richard J Perrin, et al.
Published: (2011-01-01) -
Autoantibody profiling on human proteome microarray for biomarker discovery in cerebrospinal fluid and sera of neuropsychiatric lupus.
by: Chaojun Hu, et al.
Published: (2015-01-01) -
High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid.
by: Ronald C Hendrickson, et al.
Published: (2015-01-01) -
Establishing the proteome of normal human cerebrospinal fluid.
by: Steven E Schutzer, et al.
Published: (2010-06-01) -
Label-Free Quantitative Proteome Profiling of Cerebrospinal Fluid from a Rat Stroke Model with Stem Cell Therapy
by: Junseok W Hur MD, PhD, et al.
Published: (2021-06-01)